Table 3.
Antibiotic resistance patterns of different S. enterica serotypes isolated from stools over a 2-year period.
| Serotype | AMP | AMX/CLA | TIC | PIP | CTX | CRO | NAL | CIP | NFX | CMP | TET | TMP-SMX | NTR | Resistant to ≥4 abx* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S. Enteritidis | 0a | 0 | 0 | 0 | 0 | 0 | 17.8 | 0 | 0 | 0 | 0 | 1.8 | 60.7 | 0 |
| 0/56b | 0/56 | 0/56 | 0/56 | 0/56 | 0/56 | 10/56 | 0/56 | 0/56 | 0/56 | 0/56 | 1/56 | 34/56 | 0/56 | |
|
| ||||||||||||||
| S. Typhimurium | 20.9 | 7 | 20.9 | 20.9 | 0 | 0 | 0 | 0 | 0 | 7 | 30.2 | 23.3 | 34.9 | 9.3 |
| 9/43 | 3/43 | 9/43 | 9/43 | 0/43 | 0/43 | 0/43 | 0/43 | 0/43 | 3/43 | 13/43 | 10/43 | 15/43 | 4/43 | |
|
| ||||||||||||||
| S. Newport | 0 | 0 | 0 | 0 | 0 | 0 | 7.7 | 0 | 0 | 0 | 7.7 | 0 | 92.3 | 0 |
| 0/13 | 0/13 | 0/13 | 0/13 | 0/13 | 0/13 | 1/13 | 0/13 | 0/13 | 0/31 | 1/13 | 0/31 | 12/13 | 0/13 | |
|
| ||||||||||||||
| S. Hadar | 60 | 40 | 60 | 60 | 0 | 0 | 80 | 0 | 0 | 0 | 60 | 0 | 20 | 60 |
| 3/5 | 2/5 | 3/5 | 3/5 | 0/5 | 0/5 | 4/5 | 0/5 | 0/5 | 0/5 | 3/5 | 0/5 | 1/5 | 3/5 | |
|
| ||||||||||||||
| Others | 6.1 | 3 | 9.1 | 9.1 | 0 | 0 | 15.1 | 6.1 | 6.1 | 0 | 18.2 | 6.1 | 30.3 | 0 |
| 2/33 | 1/33 | 3/33 | 3/33 | 0/33 | 0/33 | 5/33 | 2/33 | 2/33 | 0/33 | 6/33 | 2/33 | 10/33 | 0/33 | |
|
| ||||||||||||||
| Total | 9.3 | 4 | 10 | 10 | 0 | 0 | 13.3 | 1.3 | 1.3 | 2 | 15.3 | 8.7 | 48 | 4.7 |
| 14/150 | 6/150 | 15/150 | 15/150 | 0/631 | 0/631 | 20/150 | 2/150 | 2/150 | 3/150 | 23/150 | 13/150 | 72/150 | 7/150 | |
*abx: antibiotics.
AMP: ampicillin; AMX/CLA: amoxicillin-clavulanic acid; TIC: ticarcillin; PIP: piperacillin; CTX: cefotaxime; CRO: ceftriaxone; NAL: nalidixic acid; CIP: ciprofloxacin; NFX: norfloxacin; CMP: chloramphenicol; TET: tetracycline; TMP-SMX: cotrimoxazole; NTR: nitrofurantoin.
a% (percentage of resistant isolates/serotype).
bNumber of resistant isolates/total number of isolates in serotype.